Bestatin (Ubenimex)

Bestatin (ubenimex) is a dipeptide analog isolated from Streptomyces olivoreticuli that potently inhibits aminopeptidases, particularly aminopeptidase N (APN/CD13) and leucine aminopeptidase. The compound contains an unusual alpha-hydroxy-beta-amino acid (AHPA) that mimics the transition state of aminopeptidase catalysis.

Beyond enzyme inhibition, bestatin demonstrates immunomodulatory properties that led to its clinical approval in Japan as an adjunct therapy for acute myeloid leukemia. The immunoenhancing effects include increased natural killer cell activity, enhanced T-cell proliferation, and augmented cytokine production, though the precise mechanisms linking aminopeptidase inhibition to immune enhancement are still under investigation.

Aminopeptidase N (CD13) is expressed on myeloid cells, intestinal epithelium, and tumor vasculature, and plays roles in antigen presentation, cell migration, and angiogenesis. CD13 inhibition may contribute to bestatin's anti-tumor effects through both immune enhancement and direct anti-angiogenic activity.

Research applications include studying aminopeptidase function in protein processing, investigating CD13's role in tumor biology and metastasis, and exploring pain modulation through inhibition of enkephalin-degrading enzymes. Bestatin is orally bioavailable, distinguishing it from many peptide-based protease inhibitors and enabling systemic administration in research and clinical settings.